L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain
- 1 May 1995
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 10 (3), 295-297
- https://doi.org/10.1002/mds.870100311
Abstract
There is evidence for a 37% deficiency of complex I activity in Parkinson's disease (PD), which appears to be specific for PD amongst parkinsonian syndromes and selective for the substantia nigra within the central nervous system. Rat studies have shown that, in the context of a normal nigrostriatal dopaminergic cell population, L-dihydroxyphenylalanine (L-dopa) causes a reversible 25% defect of complex I activity in nigral and striatal tissue. Analysis of striatal tissue from PD patients after prolonged exposure to highdose L-dopa does not show such a defect. Results of these and other studies suggest that L-dopa therapy does not cause complex I deficiency in PD striatum. However, it cannot be excluded that, in the particular environment of the PD substantia nigra, L-dopa may enhance a preexisting complex I defect.Keywords
This publication has 14 references indexed in Scilit:
- Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisalMovement Disorders, 1994
- BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASEBrain, 1992
- Sequential damage in mitochondrial complexes by peroxidative stressNeurochemical Research, 1991
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991
- L-dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondriaMovement Disorders, 1991
- Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990
- Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in cultureJournal of Neuroscience Research, 1990
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990
- Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year periodMovement Disorders, 1986
- Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa ChronicallyJournal of Neurochemistry, 1984